Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AZN AstraZeneca	$69.85 -0.3%	$70.55	$61.24 ▼ $87.68	$216.63B	0.38	5.21 million shs	3.13 million shs
EBS Emergent Biosolutions	$6.35 -7.1%	$6.00	$4.02 ▼ $15.10	$344.41M	2.1	1.79 million shs	8.65 million shs
FATE Fate Therapeutics	$1.04 -5.5%	$1.23	$0.66 ▼ $5.92	$119.19M	2.23	2.22 million shs	3.75 million shs
JNJ Johnson & Johnson	$152.44 +0.3%	$153.85	$140.68 ▼ $169.99	$366.78B	0.42	8.02 million shs	10.00 million shs
MRNA Moderna	$27.16 -1.4%	$26.36	$23.15 ▼ $129.39	$10.50B	1.86	8.54 million shs	11.54 million shs
PFE Pfizer	$24.20 -0.2%	$23.42	$20.92 ▼ $31.54	$137.56B	0.57	41.29 million shs	39.50 million shs
UNH UnitedHealth Group	$308.85 +2.1%	$339.15	$248.88 ▼ $630.73	$280.17B	0.44	7.45 million shs	13.58 million shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AZN AstraZeneca	+0.56%	-0.98%	-1.25%	-5.04%	-11.39%
EBS Emergent Biosolutions	+1.41%	+8.37%	+8.15%	+46.20%	+4.11%
FATE Fate Therapeutics	-5.17%	-9.09%	-9.84%	+29.52%	-66.26%
JNJ Johnson & Johnson	-0.05%	+0.98%	-0.65%	-6.95%	+3.71%
MRNA Moderna	+2.53%	+8.43%	+2.91%	-11.50%	-77.51%
PFE Pfizer	+0.06%	+1.80%	+2.94%	-3.56%	-11.36%
UNH UnitedHealth Group	+0.08%	-1.46%	+2.52%	-41.33%	-37.53%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AZN AstraZeneca	2.2938 of 5 stars	2.4	3.0	1.7	0.0	2.9	0.0	1.3
EBS Emergent Biosolutions	4.1597 of 5 stars	3.5	1.0	0.0	4.6	1.3	2.5	1.3
FATE Fate Therapeutics	4.1477 of 5 stars	3.1	3.0	0.0	4.7	2.6	1.7	0.6
JNJ Johnson & Johnson	4.9566 of 5 stars	3.3	5.0	4.2	3.9	3.0	1.7	1.9
MRNA Moderna	4.5365 of 5 stars	4.0	2.0	0.0	4.6	1.4	2.5	1.3
PFE Pfizer	4.866 of 5 stars	2.3	3.0	4.2	4.3	2.9	1.7	3.1
UNH UnitedHealth Group	4.9978 of 5 stars	4.3	3.0	4.2	4.0	2.9	3.3	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AZN AstraZeneca	2.83	Moderate Buy	$85.00	21.69% Upside
EBS Emergent Biosolutions	3.00	Buy	$14.33	125.90% Upside
FATE Fate Therapeutics	2.13	Hold	$3.83	268.59% Upside
JNJ Johnson & Johnson	2.55	Moderate Buy	$170.88	12.10% Upside
MRNA Moderna	2.04	Hold	$46.61	71.62% Upside
PFE Pfizer	2.53	Moderate Buy	$29.17	20.54% Upside
UNH UnitedHealth Group	2.60	Moderate Buy	$415.57	34.55% Upside

Current Analyst Ratings Breakdown

Latest JNJ, UNH, PFE, MRNA, EBS, AZN, and FATE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/25/2025	UNH UnitedHealth Group	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$400.00 ➝ $385.00
6/20/2025	UNH UnitedHealth Group	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$405.00 ➝ $418.00
6/12/2025	FATE Fate Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
6/11/2025	UNH UnitedHealth Group	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/11/2025	UNH UnitedHealth Group	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$312.00
6/6/2025	UNH UnitedHealth Group	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
6/5/2025	JNJ Johnson & Johnson	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$181.00
6/3/2025	UNH UnitedHealth Group	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$552.00 ➝ $353.00
6/2/2025	MRNA Moderna	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
6/2/2025	UNH UnitedHealth Group	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$350.00
6/2/2025	UNH UnitedHealth Group	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$450.00 ➝ $400.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AZN AstraZeneca	$54.07B	4.01	$6.31 per share	11.07	$13.18 per share	5.30
EBS Emergent Biosolutions	$1.04B	0.33	$1.81 per share	3.50	$8.91 per share	0.71
FATE Fate Therapeutics	$13.34M	8.94	N/A	N/A	$2.80 per share	0.37
JNJ Johnson & Johnson	$88.82B	4.13	$13.13 per share	11.61	$29.69 per share	5.13
MRNA Moderna	$3.24B	3.25	N/A	N/A	$28.33 per share	0.96
PFE Pfizer	$63.63B	2.16	$4.35 per share	5.56	$15.62 per share	1.55
UNH UnitedHealth Group	$400.28B	0.70	$33.10 per share	9.33	$106.78 per share	2.89

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AZN AstraZeneca	$7.04B	$2.49	28.05	13.97	1.28	14.14%	33.14%	12.83%	7/24/2025 (Estimated)
EBS Emergent Biosolutions	-$190.60M	-$2.71	N/A	3.07	N/A	-13.63%	-0.52%	-0.17%	8/5/2025 (Estimated)
FATE Fate Therapeutics	-$186.26M	-$1.49	N/A	N/A	N/A	-1,318.93%	-47.17%	-34.60%	8/12/2025 (Estimated)
JNJ Johnson & Johnson	$14.07B	$8.99	16.96	13.77	2.31	24.42%	33.46%	13.30%	7/16/2025 (Estimated)
MRNA Moderna	-$3.56B	-$8.73	N/A	N/A	N/A	-105.67%	-28.69%	-21.94%	7/30/2025 (Estimated)
PFE Pfizer	$8.03B	$1.38	17.53	7.99	0.88	12.62%	20.33%	8.53%	8/5/2025 (Estimated)
UNH UnitedHealth Group	$14.41B	$23.88	12.93	9.30	1.43	5.39%	26.29%	8.67%	7/15/2025 (Estimated)

Latest JNJ, UNH, PFE, MRNA, EBS, AZN, and FATE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/24/2025	Q2 2025	AZN AstraZeneca	$1.11	N/A	N/A	N/A	N/A	N/A
7/16/2025	Q2 2025	JNJ Johnson & Johnson	$2.65	N/A	N/A	N/A	$22.85 billion	N/A
5/13/2025	Q1 2025	FATE Fate Therapeutics	-$0.39	-$0.32	+$0.07	-$0.32	$1.18 million	$1.63 million
5/7/2025	Q1 2025	EBS Emergent Biosolutions	$0.49	$0.71	+$0.22	$1.19	$218.50 million	$222.20 million
5/1/2025	Q1 2025	MRNA Moderna	-$2.92	-$2.52	+$0.40	-$2.52	$130.35 million	$108.00 million
4/29/2025	Q1 2025	AZN AstraZeneca	$1.10	$1.24	+$0.14	$0.93	$13.71 billion	$13.59 billion
4/29/2025	Q1 2025	PFE Pfizer	$0.67	$0.92	+$0.25	$0.52	$14.43 billion	$13.72 billion
4/17/2025	Q1 2025	UNH UnitedHealth Group	$7.29	$7.20	-$0.09	$6.85	$111.56 billion	$109.58 billion
4/15/2025	Q1 2025	JNJ Johnson & Johnson	$2.59	$2.77	+$0.18	$4.54	$21.65 billion	$21.89 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AZN AstraZeneca	$2.06	2.95%	N/A	82.73%	N/A
EBS Emergent Biosolutions	N/A	N/A	N/A	N/A	N/A
FATE Fate Therapeutics	N/A	N/A	N/A	N/A	N/A
JNJ Johnson & Johnson	$5.20	3.41%	N/A	57.84%	64 Years
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
PFE Pfizer	$1.72	7.11%	N/A	124.64%	16 Years
UNH UnitedHealth Group	$8.84	2.86%	N/A	37.02%	15 Years

Latest JNJ, UNH, PFE, MRNA, EBS, AZN, and FATE Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/25/2025	PFE Pfizer	quarterly	$0.43	7.08%	7/25/2025	7/25/2025	9/2/2025
6/5/2025	UNH UnitedHealth Group	quarterly	$2.21	3%	6/16/2025	6/16/2025	6/24/2025
4/23/2025	PFE Pfizer	quarterly	$0.43	7.69%	5/9/2025	5/9/2025	6/13/2025
4/15/2025	JNJ Johnson & Johnson	quarterly	$1.30	3.37%	5/27/2025	5/27/2025	6/10/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AZN AstraZeneca	0.65	0.90	0.70
EBS Emergent Biosolutions	1.20	6.32	3.51
FATE Fate Therapeutics	N/A	8.81	8.81
JNJ Johnson & Johnson	0.49	1.26	1.03
MRNA Moderna	N/A	4.22	4.14
PFE Pfizer	0.64	1.26	0.96
UNH UnitedHealth Group	0.71	0.85	0.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AZN AstraZeneca	20.35%
EBS Emergent Biosolutions	78.40%
FATE Fate Therapeutics	97.54%
JNJ Johnson & Johnson	69.55%
MRNA Moderna	75.33%
PFE Pfizer	68.36%
UNH UnitedHealth Group	87.86%

Insider Ownership

Company	Insider Ownership
AZN AstraZeneca	N/A
EBS Emergent Biosolutions	1.20%
FATE Fate Therapeutics	5.51%
JNJ Johnson & Johnson	0.16%
MRNA Moderna	11.00%
PFE Pfizer	0.06%
UNH UnitedHealth Group	0.28%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AZN AstraZeneca	94,300	3.10 billion	N/A	Optionable
EBS Emergent Biosolutions	2,420	54.28 million	53.63 million	Optionable
FATE Fate Therapeutics	550	114.60 million	108.29 million	Optionable
JNJ Johnson & Johnson	138,100	2.41 billion	2.40 billion	Optionable
MRNA Moderna	5,800	386.74 million	344.20 million	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable
UNH UnitedHealth Group	400,000	907.14 million	904.60 million	Optionable

JNJ, UNH, PFE, MRNA, EBS, AZN, and FATE Headlines

Recent News About These Companies

UnitedHealth Group (UNH) Reshuffles Leadership Amidst Revenue Fluctuations

June 27 at 8:54 AM | gurufocus.com

Money Concepts Capital Corp Increases Position in UnitedHealth Group Incorporated (NYSE:UNH)

June 27 at 8:32 AM | marketbeat.com

Achmea Investment Management B.V. Acquires 18,734 Shares of UnitedHealth Group Incorporated (NYSE:UNH)

June 27 at 8:18 AM | marketbeat.com

Waverton Investment Management Ltd Increases Position in UnitedHealth Group Incorporated (NYSE:UNH)

June 27 at 8:16 AM | marketbeat.com

Border to Coast Pensions Partnership Ltd Lowers Stock Position in UnitedHealth Group Incorporated (NYSE:UNH)

June 27 at 7:55 AM | marketbeat.com

UnitedHealth Group Incorporated (NYSE:UNH) Shares Sold by Bartlett & CO. Wealth Management LLC

June 27 at 7:46 AM | marketbeat.com

UnitedHealth Group Incorporated (NYSE:UNH) Shares Bought by Illinois Municipal Retirement Fund

June 27 at 7:26 AM | marketbeat.com

Park Place Capital Corp Boosts Holdings in UnitedHealth Group Incorporated (NYSE:UNH)

June 27 at 6:41 AM | marketbeat.com

Diversified Trust Co Has $25.11 Million Position in UnitedHealth Group Incorporated (NYSE:UNH)

June 27 at 6:41 AM | marketbeat.com

1,428 Shares in UnitedHealth Group Incorporated (NYSE:UNH) Purchased by Falcon Wealth Planning

June 27 at 6:19 AM | marketbeat.com

CNB Bank Has $2.04 Million Stock Holdings in UnitedHealth Group Incorporated (NYSE:UNH)

June 27 at 5:49 AM | marketbeat.com

First Merchants Corp Cuts Stock Holdings in UnitedHealth Group Incorporated (NYSE:UNH)

June 27 at 5:49 AM | marketbeat.com

Perpetual Ltd Sells 11,815 Shares of UnitedHealth Group Incorporated (NYSE:UNH)

June 27 at 5:41 AM | marketbeat.com

UnitedHealth Group (NYSE:UNH) Trading Down 1.4% Following Analyst Downgrade

June 27 at 2:19 AM | americanbankingnews.com

JPMorgan Raised the PT on UnitedHealth Group (UNH), Keeps a Buy Rating

June 26 at 11:48 PM | msn.com

3 Reasons Warren Buffett Might Buy UnitedHealth Group Stock

June 26 at 11:48 PM | aol.comA

UnitedHealth appoints new CEO to run health services division

June 26 at 5:13 PM | reuters.com

UnitedHealth Group (NYSE:UNH) Stock Price Up 1.2% - Time to Buy?

June 26 at 2:41 PM | marketbeat.com

This Dividend Growth Stock Is Down 50%. Back Up the Truck or Put It in Park and Wait?

June 26 at 11:16 AM | 247wallst.com

UnitedHealth Group Incorporated Investor Alert (NYSE: UNH): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors Following DOJ Probe and for Possible False Statements

June 26 at 11:00 AM | prnewswire.com

UnitedHealth Group Incorporated (NYSE:UNH) is Conning Inc.'s 3rd Largest Position

June 26 at 8:08 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
Lululemon, UNH, Enphase: Bad News, Good Opportunity?
By Thomas Hughes | June 17, 2025
View Lululemon, UNH, Enphase: Bad News, Good Opportunity?
UnitedHealth Stock Dips: Is This a Value Buy Opportunity?
By Jeffrey Neal Johnson | June 13, 2025
View UnitedHealth Stock Dips: Is This a Value Buy Opportunity?
3 Oversold Stocks Flashing Bullish Reversal Signals
By Sam Quirke | June 7, 2025
View 3 Oversold Stocks Flashing Bullish Reversal Signals
Congress’s May Stock Trades: What They Know That You Don’t
By Thomas Hughes | June 20, 2025
View Congress’s May Stock Trades: What They Know That You Don’t

JNJ, UNH, PFE, MRNA, EBS, AZN, and FATE Company Descriptions

AstraZeneca NASDAQ:AZN

$69.85 -0.22 (-0.31%)

Closing price 04:00 PM Eastern

Extended Trading

$69.85 0.00 (0.00%)

As of 06:20 PM Eastern

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Emergent Biosolutions NYSE:EBS

$6.34 -0.49 (-7.10%)

Closing price 03:59 PM Eastern

Extended Trading

$6.47 +0.13 (+1.97%)

As of 06:11 PM Eastern

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Fate Therapeutics NASDAQ:FATE

$1.04 -0.06 (-5.45%)

Closing price 04:00 PM Eastern

Extended Trading

$1.05 +0.01 (+0.96%)

As of 05:40 PM Eastern

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Johnson & Johnson NYSE:JNJ

$152.44 +0.43 (+0.28%)

Closing price 03:59 PM Eastern

Extended Trading

$152.26 -0.18 (-0.12%)

As of 06:26 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Moderna NASDAQ:MRNA

$27.16 -0.38 (-1.38%)

Closing price 04:00 PM Eastern

Extended Trading

$27.15 -0.01 (-0.04%)

As of 06:27 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Pfizer NYSE:PFE

$24.20 -0.04 (-0.18%)

Closing price 03:59 PM Eastern

Extended Trading

$24.18 -0.01 (-0.05%)

As of 06:27 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

UnitedHealth Group NYSE:UNH

$308.85 +6.23 (+2.06%)

Closing price 03:59 PM Eastern

Extended Trading

$307.80 -1.05 (-0.34%)

As of 06:29 PM Eastern

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage. The Optum Health segment provides care delivery, care management, wellness and consumer engagement, and health financial services patients, consumers, care delivery systems, providers, employers, payers, and public-sector entities. The Optum Insight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The Optum Rx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and community health pharmacy services, infusion, and purchasing and clinical capabilities, as well as develops programs in the areas of step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated was founded in 1974 and is based in Minnetonka, Minnesota.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest JNJ, UNH, PFE, MRNA, EBS, AZN, and FATE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest JNJ, UNH, PFE, MRNA, EBS, AZN, and FATE Earnings

Compare Dividends

Latest JNJ, UNH, PFE, MRNA, EBS, AZN, and FATE Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

JNJ, UNH, PFE, MRNA, EBS, AZN, and FATE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

JNJ, UNH, PFE, MRNA, EBS, AZN, and FATE Company Descriptions

AstraZeneca NASDAQ:AZN

Emergent Biosolutions NYSE:EBS

Fate Therapeutics NASDAQ:FATE

Johnson & Johnson NYSE:JNJ

Moderna NASDAQ:MRNA

Pfizer NYSE:PFE

UnitedHealth Group NYSE:UNH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools